Medicus Posts Wider Loss In Q2 Due To Higher Expenses; Stock Up
(RTTNews) - Medicus Pharma Ltd. (MDCX), a clinical-stage biotech company, reported second quarter results showing a wider loss due to higher expenses, mainly associated with operating and interest expenses.
Company Profile
Medicus is focused on advancing therapeutic assets in dermatology, oncology and urology. Its lead programs include SkinJect, a doxorubicin-containing dissolvable microneedle array being developed for basal cell carcinoma and Gorlin syndrome.
The other candidate, Teverelix, a next-generation GnRH antagonist is being evaluated in advanced prostate cancer and acute urinary retention.
Second Quarter Highlights
For the second quarter ended June 30, 2026, loss attributable to common shareholders expanded by 89% to $11.62 million, compared to a loss of $6.12 million in the previous year.
On a per share basis, loss was $0.21 from $0.43 in 2025.
The company recorded total operating expenses of $11.48 million for the second quarter, while last year the expenses were $6.02 million.
The interest accounted for an expense of $0.20 million in Q2 2026, which was absent a year ago.
Clinical Update
SkinJect
Medicus reported additional pre-specified analyses from the completed Phase 2 SKNJCT-003 study, with the 200 µg dose showing 64% clinical clearance and 55% histological clearance.
The company also received FDA's "Study May Proceed" authorization to initiate the registrational SKNJCT-005 trial in patients with Gorlin Syndrome.
Teverelix
The company received Institutional Review Board (IRB) authorization and positive FDA feedback for an optimized Phase 2 study evaluating Teverelix to prevent recurrence of acute urinary retention.
Medicus also received UAE Department of Health authorization to initiate the genomics-enabled Phase 2 PRECISION-E2 study in women with symptomatic endometriosis.
Business Highlights
The company has advanced strategic initiatives across its multi-asset portfolio, including evaluating acquisition, licensing and partnering opportunities. The company also strengthened its financial position through multiple financing initiatives, raising approximately $40 million in equity and debt financing year to date.
Cash Position
Cash, cash equivalents and restricted cash as of June 30, 2026, totaled $25.19 million.
The Road Ahead
In the upcoming quarters, Medicus expects continued clinical and regulatory progress, strategic partnerships, licensing opportunities, and financing initiatives to advance its pipeline, particularly SkinJect.
Stock Quote
On Thursday, MDCX closed at $0.17, down 34.40%. In the overnight trading, the stock is up 4.75% at $0.17.
